LED Medical Diagnostics Inc.
TSX VENTURE : LMD
OTCQX : LEDIF
FRANKFURT : LME

LED Medical Diagnostics Inc.

October 24, 2013 20:00 ET

LED Medical Diagnostics Inc. Announces Appointment of Lamar Roberts as Vice President of Sales and Marketing

BURNABY, BRITISH COLUMBIA--(Marketwired - Oct. 24, 2013) - LED Medical Diagnostics Inc. ("LED" or the "Company") (TSX VENTURE:LMD)(OTCQX:LEDIF)(FRANKFURT:LME) announced today that it has appointed Mr. Lamar Roberts to the role of Vice President of Sales and Marketing.

Mr. Roberts has held Senior Executive positions with 360imaging, Carestream Dental and PracticeWorks and has developed an industry reputation for guiding companies from early growth stages to becoming industry leaders. He also has a strong background in leading commercial efforts in technical, medical, and geographically dispersed organizations. "I have had the rare pleasure of witnessing Lamar's leadership capabilities and unwavering focus on growth while working with him at Carestream LLC. We are excited that Lamar has chosen to bring his depth of knowledge to our team at LED Medical. The Company is at an important juncture in its corporate growth and Lamar is exactly the right person to guide it to international leadership in its market sector," states Dr. David Gane, President and CEO.

LED Medical's VELscope® is the world's most frequently used technology to assist clinicians in screening for oral tissue anomalies, including early stage oral cancer. Despite this accomplishment, the Company believes that this technology has significantly more clinical and commercial potential.

"This is an exciting period for LED Medical. We are assembling the very best team possible - all proven leaders in their fields - to bring their drive, creative energy and wisdom to evolve LED Medical into the world leader we all believe it can be, " states Dr. Gane.

About VELscope® Technology

According to the Oral Cancer Foundation, nearly 42,000 Americans will be diagnosed with oral or pharyngeal cancer this year. However, that is just over 8 percent of the approximately 640,000 people diagnosed annually on a worldwide basis. LED Medical's product, the VELscope® VX Enhanced Oral Assessment System, is changing the way dental practitioners examine the oral mucosa and screen for tissue abnormalities. The VELscope® Vx allows a wide variety of oral abnormalities to be detected - often before they're visible to the unassisted eye.

The VELscope Vx® is further intended to be used by surgeons as a tool to assist in identifying diseased tissue around a clinically apparent lesion and thus aid in determining the appropriate margin for surgical excision.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.

Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 12,000 VELscope® Vx systems sold globally and they have been used to perform more than 25 million exams. For more information, call 604.434.4614 or visit www.leddental.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • For media or investor relations, please contact:
    LED Medical Diagnostics Inc.
    Mark Komonoski, Investor Relations
    (403) 255-8483 / Toll-Free: (877) 255-8483
    Cell: (403) 470-8384
    mark.komonoski@ledmd.com / Skype: mkomonoski